Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Volatility and Risk
Cidara Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cidara Therapeutics and Kymera Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cidara Therapeutics | $63.90 million | 0.87 | -$22.93 million | ($7.68) | -1.58 |
| Kymera Therapeutics | $78.59 million | 23.55 | -$146.96 million | ($2.51) | -12.02 |
Profitability
This table compares Cidara Therapeutics and Kymera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cidara Therapeutics | -73.46% | -201.62% | -54.25% |
| Kymera Therapeutics | -194.67% | -31.92% | -23.98% |
Institutional & Insider Ownership
35.8% of Cidara Therapeutics shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings for Cidara Therapeutics and Kymera Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cidara Therapeutics | 0 | 0 | 3 | 1 | 3.25 |
| Kymera Therapeutics | 0 | 6 | 6 | 0 | 2.50 |
Cidara Therapeutics presently has a consensus target price of $71.25, indicating a potential upside of 485.94%. Kymera Therapeutics has a consensus target price of $42.70, indicating a potential upside of 41.58%. Given Cidara Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Cidara Therapeutics is more favorable than Kymera Therapeutics.
Summary
Kymera Therapeutics beats Cidara Therapeutics on 8 of the 15 factors compared between the two stocks.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
